Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

被引：0
|
作者：
Amrein, Philip C.
Attar, Eyal C.
Fathi, Amir Tahmasb
McAfee, Steven L.
Wadleigh, Martha
DeAngelo, Daniel J.
Steensma, David P.
Foster, Julia
Stone, Richard M.
Neuberg, Donna S.
Ballen, Karen K.
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[2] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6621
引用
收藏
页数：1
相关论文
共 50 条
  • [21] End of Life (EOL) Metrics in Older Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    LoCastro, M.
    Baran, A. M.
    Liesveld, J.
    Becker, M. W.
    O'Dwyer, K. M.
    Husehon, E.
    Aljitawi, O. S.
    Baumgart, M.
    Snyder, E.
    Kluger, B.
    Mendler, J. H.
    Loh, K.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S285 - S285
  • [22] A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Watts, Justin M.
    Baer, Maria R.
    Lee, Sangmin
    Yang, Jay
    Dinner, Shira Naomi
    Prebet, Thomas
    Schiller, Gary J.
    Seiter, Karen
    Ferrell, Paul Brent
    Kelly, Patrick Francis
    Li, Ping
    Sweeney, Jennifer
    Watson, Courtney
    Mohamed, Hesham
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] HEXAMETHYLENE BISACETAMIDE (HMBA) IN MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    ANDREEFF, M
    STONE, R
    YOUNG, C
    TONG, W
    ERVIN, T
    TAFURI, A
    KOLITZ, J
    RIFKIND, R
    KUFE, D
    MARKS, P
    LEUKEMIA, 1991, 5 (02) : 174 - 174
  • [24] Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following a diagnosis of breast cancer
    Padmanabhan, A.
    Block, A.
    Sait, S.
    Ford, L. A.
    O'Connor, T. L.
    Moysich, K. B.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Navada, Shyamala C.
    Baer, Maria R.
    Raza, Azra
    Greenberg, Peter
    Kreuzer, Karl-Anton
    Hiwase, Devendra K.
    Roboz, Gail J.
    Santini, Valeria
    Platzbecker, Uwe
    Petrone, Michael E.
    Brownstein, Bernard
    Zbyszewski, Patrick Simon
    Maniar, Manoj
    Silverman, Lewis R.
    BLOOD, 2016, 128 (22)
  • [26] A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).
    Foster, Matthew C.
    Amin, Chirag
    Voorhees, Peter M.
    Van Deventer, Hendrik W.
    Richards, Kristy L.
    Ivanova, Anastasia
    Whitman, Jennifer
    Shea, Thomas C.
    BLOOD, 2009, 114 (22) : 808 - 809
  • [27] A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Kohrt, Holbrook E.
    Gallegos, Leonel
    Berube, Caroline
    Coutre, Steven
    Gotlib, Jason
    Liedtke, Michaela
    Mitchell, Beverly S.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 1347 - 1347
  • [28] MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIAS (AML) WITH MYELOFIBROSIS
    IMBERT, M
    NGUYEN, D
    SULTAN, C
    LEUKEMIA RESEARCH, 1992, 16 (01) : 51 - 54
  • [29] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    BLOOD, 2011, 118 (21) : 1122 - 1122
  • [30] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345